We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Metabolic Reprogramming by Malat1 Depletion in Prostate Cancer.
- Authors
Nanni, Simona; Aiello, Aurora; Salis, Chiara; Re, Agnese; Cencioni, Chiara; Bacci, Lorenza; Pierconti, Francesco; Pinto, Francesco; Ripoli, Cristian; Ostano, Paola; Baroni, Silvia; Lazzarino, Giacomo; Tavazzi, Barbara; Pugliese, Dario; Bassi, PierFrancesco; Grassi, Claudio; Panunzi, Simona; Chiorino, Giovanna; Pontecorvi, Alfredo; Gaetano, Carlo
- Abstract
Simple Summary: Prostate cancer (PCa) is one of the most common cancers in developed countries, being the second leading cause of cancer death among men. Surgery is the primary therapeutic option, but about one-third of patients develop a recurrence within ten years, for which successful therapy is unavailable. Based on these observations, it has become urgent to develop novel molecular tools for predicting clinical outcome. Here, we focus on one of the best characterized cancer-associated long non-coding transcripts, namely metastasis-associated lung adenocarcinoma transcript 1 (MALAT1). This study highlighted a novel role for MALAT1 as a controller of prostate cancer metabolism. MALAT1 silencing caused a metabolic rewire in both experimental models adopted, prostate cancer cell lines, and organotypic slice cultures derived from surgical specimens. PCa cells upon MALAT1 silencing revert their phenotype towards glycolysis, which is characteristic of normal prostate cells. In this regard, MALAT1 targeting may represent a promising diagnostic tool and a novel therapeutic option. The lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) promotes growth and progression in prostate cancer (PCa); however, little is known about its possible impact in PCa metabolism. The aim of this work has been the assessment of the metabolic reprogramming associated with MALAT1 silencing in human PCa cells and in an ex vivo model of organotypic slice cultures (OSCs). Cultured cells and OSCs derived from primary tumors were transfected with MALAT1 specific gapmers. Cell growth and survival, gene profiling, and evaluation of targeted metabolites and metabolic enzymes were assessed. Computational analysis was made considering expression changes occurring in metabolic markers following MALAT1 targeting in cultured OSCs. MALAT1 silencing reduced expression of some metabolic enzymes, including malic enzyme 3, pyruvate dehydrogenase kinases 1 and 3, and choline kinase A. Consequently, PCa metabolism switched toward a glycolytic phenotype characterized by increased lactate production paralleled by growth arrest and cell death. Conversely, the function of mitochondrial succinate dehydrogenase and the expression of oxidative phosphorylation enzymes were markedly reduced. A similar effect was observed in OSCs. Based on this, a predictive algorithm was developed aimed to predict tumor recurrence in a subset of patients. MALAT1 targeting by gapmer delivery restored normal metabolic energy pathway in PCa cells and OSCs.
- Subjects
ENERGY metabolism; ADENOCARCINOMA; LUNG cancer; RNA; CANCER relapse; TRANSFERASES; OXIDOREDUCTASES; PROSTATE tumors; PHENOTYPES; CELL death
- Publication
Cancers, 2021, Vol 13, Issue 1, p15
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13010015